{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Al Jurdi A"],"funding":["Massachusetts General Hospital"],"pagination":["3130-3136"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9906353"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(12)"],"pubmed_abstract":["The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS-CoV-2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety of tixagevimab/cilgavimab in vaccinated solid organ transplant recipients during the Omicron wave is limited. To address this, we conducted a retrospective cohort study comparing 222 solid organ transplant recipients (SOTRs) who received tixagevimab/cilgavimab for pre-exposure prophylaxis and 222 vaccine-matched solid organ transplant recipients who did not receive tixagevimab/cilgavimab. Breakthrough SARS-CoV-2 infections occurred in 11 (5%) of SOTRs who received tixagevimab/cilgavimab and in 32 (14%) of SOTRs in the control group (p <"],"journal":["American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons"],"pubmed_title":["Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave."],"pmcid":["PMC9906353"],"funding_grant_id":["Harold and Ellen Danser Endowed/Distinguished Chai"],"pubmed_authors":["Riella LV","Bethea E","Azzi J","Al Jurdi A","Morena L","Cote M"],"additional_accession":[]},"is_claimable":false,"name":"Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.","description":"The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS-CoV-2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on the efficacy and safety of tixagevimab/cilgavimab in vaccinated solid organ transplant recipients during the Omicron wave is limited. To address this, we conducted a retrospective cohort study comparing 222 solid organ transplant recipients (SOTRs) who received tixagevimab/cilgavimab for pre-exposure prophylaxis and 222 vaccine-matched solid organ transplant recipients who did not receive tixagevimab/cilgavimab. Breakthrough SARS-CoV-2 infections occurred in 11 (5%) of SOTRs who received tixagevimab/cilgavimab and in 32 (14%) of SOTRs in the control group (p <","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-04T23:51:55.867Z","creation":"2025-04-04T23:51:55.867Z"},"accession":"S-EPMC9906353","cross_references":{"pubmed":["35727916"],"doi":["10.1111/ajt.17128"]}}